CHF6.15
5.96% yesterday
SIX Swiss Exchange, Apr 04, 05:30 pm CET
ISIN
IT0004147952
Symbol
NWRN
Sector
Industry

Newron Pharmaceutical Stock price

CHF6.15
-2.91 32.12% 1M
-1.51 19.71% 6M
-2.80 31.28% YTD
-2.00 24.54% 1Y
+4.82 362.41% 3Y
+1.04 20.35% 5Y
-24.45 79.90% 10Y
SIX Swiss Exchange, Closing price Fri, Apr 04 2025
-0.39 5.96%
ISIN
IT0004147952
Symbol
NWRN
Sector
Industry

Key metrics

Market capitalization CHF122.75m
Enterprise Value CHF160.89m
P/E (TTM) P/E ratio 8.71
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.31
P/S ratio (TTM) P/S ratio 2.53
P/B ratio (TTM) P/B ratio 89.72
Revenue growth (TTM) Revenue growth 450.19%
Revenue (TTM) Revenue CHF48.56m
EBIT (operating result TTM) EBIT CHF24.57m
Free Cash Flow (TTM) Free Cash Flow CHF-16.64m
EPS (TTM) EPS CHF0.71
P/E forward negative
P/S forward 11.40
EV/Sales forward 14.94
Show more

Is Newron Pharmaceutical a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Newron Pharmaceutical Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Newron Pharmaceutical:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Newron Pharmaceutical:

Buy
100%

Financial data from Newron Pharmaceutical

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Dec '24
+/-
%
49 49
450% 450%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 11 11
53% 53%
22%
- Research and Development Expense 13 13
2% 2%
27%
25 25
324% 324%
51%
- Depreciation and Amortization 0.18 0.18
10% 10%
0%
EBIT (Operating Income) EBIT 25 25
318% 318%
51%
Net Profit 15 15
194% 194%
30%

In millions CHF.

Don't miss a Thing! We will send you all news about Newron Pharmaceutical directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Newron Pharmaceutical Stock News

AD HOC NEWS
4 days ago
Newron Pharmaceuticals S.p.A. / IT0004147952
More Newron Pharmaceutical News

Company Profile

Newron Pharmaceuticals SpA operates as a biopharmaceutical company. It focuses on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The firm's products include Xadago (safinamide), Evenamide (NW-3509) and Ralfinamide. The company was founded by Luca Benatti, Ruggero Fariello and Patricia Salvati in 1999 and is headquartered in Bresso, Italy.

Head office Italy
CEO Stefan Weber
Founded 2002
Website www.newron.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today